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Summary
The p38 MAP kinase inhibitor, SB 242235, was evaluated for its effects on the metabolism of bovine and human cartilage and primary
chondrocyte cultures. SB 242235 had no effect on proteoglycan synthesis (PG) in bovine articular cartilage explants (BAC), as measured by
[35S]-sulfate incorporation into glycosaminoglycans (GAGs). In addition, the compound had no effect on IL-1-induced GAG release from
these cultures. However, there was a potent, dose-dependent inhibition of nitric oxide (NO) release from IL-1-stimulated BAC with an IC50
of approximately 0.6 M, with similar effects observed in primary chondrocytes. The effect on BAC was time dependent, and mechanistically
did not appear to be the result of inhibition of protein kinase C (PKC), protein kinase A (PKA) or MEK-1. The effect on NO release in bovine
chondrocytes was at the level of inducible nitric oxide synthase (iNOS) gene expression, which was inhibited at similar concentrations as
nitrite production. In primary human chondrocytes, IL-1 induction of p38 MAP kinase was inhibited by SB 242235 with an IC50 of
approximately 1 M. Surprisingly, however, treatment of IL--stimulated human cartilage or chondrocytes with SB 242235 did not inhibit
either NO production or the induction of iNOS. On the other hand, the natural product hymenialdisine (HYM), a protein tyrosine kinase (PTK)
inhibitor, inhibited NO production and iNOS in both species. In contrast to the differential control of iNOS, PGE2 was inhibited by SB 242235
in both IL-1-stimulated bovine and human chondrocyte cultures. These studies indicate that there are species differences in the control of
iNOS by p38 inhibitors and also that different pathways may control IL-1-induced proteoglycan breakdown and NO production.
© 2000 OsteoArthritis Research Society International
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The pyridinyl imidazole compounds inhibit p38 mitogen-
activated protein (MAP) kinase and block proinflammatory
cytokine production in vitro and in vivo.1–3 These com-
pounds have been named cytokine suppressive anti-
inflammatory drugs (CSAIDs) and their molecular target
has been identified as the mitogen-activated protein kinase
homolog termed CSAID binding protein 2 (CSBP2),1 p384
or RK.5,6 Binding of the compounds to the target CSBP/p38
protein in THP1 cells has been correlated to their cytokine
biosynthesis inhibition,1,2 indicating a role for p38 in the
regulation of cytokine production in response to various
stimuli.7 Of particular relevance to the studies reported
here is that several cell types, including human articular
chondrocytes, express p38 kinase which can be activated
by IL-1.8 The ability to inhibit a number of proinflammatory
cytokines in vitro translates into pharmacological activity
in vivo for CSAIDs where they have been shown to have
therapeutic activity in a number of animal models of acute
and chronic inflammation in the absence of generalized
immunosuppression.9,10 Examples include collagen-
induced arthritis, adjuvant-induced arthritis and endotoxin
shock.3434In addition to the inhibiton of cytokines such as IL-1,
TNF- and IL-6, the CSAIDs have also been shown to
inhibit the production of nitric oxide (NO) from IL-1-
stimulated bovine cartilage explants and chondrocytes.11
These studies have shown that IL-1-mediated NO pro-
duction is due to the induction of iNOS gene expression
and this signaling involves p38 MAP kinase as SB 203580,
a p38 inhibitor, completely inhibits iNOS gene expression
and NO production.11 However, as reviewed by Lee et al.12
in in vitro kinase assays, SB 203580 inhibits p38 MAP
kinase isoform  with an IC50 of 48 nM13 and p38 with
an IC50 of 50 nM14, as well as JNK21 (IC50=280 nM)
and c-raf (IC50=360 nM).15 Recently, a more selective
inhibitor of p38 MAP kinase, SB 242235, has been shown
to be active in the adjuvant arthritic rat where it inhibits
joint inflammation as well as protecting joint integrity.16
Unlike SB 203580,17 SB 242235 has no direct inhibitory
effects on enzyme activities of 5-lipoxygenase or cyclo-
oxygenase-1 (D. Griswold, unpublished observation)
and is more selective in that it does not inhibit ERK
(IC50>100 M) and JNK1 (IC50>50 M), or JNK22
(IC50>10 M), which are structurally most related to p38
MAP kinases. Furthermore, SB 242235 exhibits differential
inhibitory effects on the four known homologs of p38 MAP
kinases, with p38 MAP kinase being 10-fold less sensitive
than p38 (IC50=19 nM) while p38 and  MAP kinases
are insensitive (IC50>10 M) (Lee et al., unpublished
observations).Address correspondence to: Alison M. Badger, SmithKline
Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia,
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REAGENTS
SB 242235 and the metalloproteinase inhibitor, BB94,
were synthesized at SmithKline Beecham Pharmaceuticals
(SB). Recombinant human IL-1 (for bovine cultures) and
IL-1 (for human cultures) were purchased from R&D
Systems Inc., Minneapolis, MN, U.S.A. Dulbecco’s modi-
fied Eagle’s medium (DMEM) and HAM’s F12 medium
were obtained from GIBCO, Grand Island, NY, U.S.A. Fetal
bovine serum (FBS) was obtained from Hyclone, Logan,
UT, U.S.A. The media were supplemented with 100 U/ml of
penicillin, 100 g/ml of streptomycin, 2.5 g/ml ampho-
tericin B and 2 mM L-glutamine (GIBCO). Dulbecco’s
phosphate buffered saline (DPBS) was obtained from
GIBCO and contained 2× antibiotics. L-ascorbic acid,
NG-monomethyl-L-arginine (NMMA), Pronase E from
Streptomyces griseus and hyaluronidase type V were from
Sigma; collagenase D from Clostridium histolyticum was
from Boehringer Mannheim, Indianapolis, IN, U.S.A.; PD
98059 was obtained from New England Biolabs Inc.,
Beverly, MA, U.S.A.; calphostin C and KT 5720 from
Calbiochem, San Diego, CA, U.S.A. 1,9-dimethylmethylene
blue (DMMB) was obtained from Aldrich Chemical Co.
(Milwaukee, WI, U.S.A.). Hymenialdisine was isolated from
the sponge Stylotella aurantium in the Department of
Biomolecular Discovery at SB. Other standard buffer
components and chemicals, unless specifically indicated
otherwise, were obtained from Sigma.CARTILAGE AND CHONDROCYTE CULTURES
Carpal metacarpal joints of calves (0–3 months old) were
obtained from Covance (Denver, PA, U.S.A.). Normal
human articular cartilage was obtained, with informed con-
sent, from the tibial plateau and femoral condyle, from
autopsy patients or patients undergoing surgery for con-
ditions other than osteoarthritis (OA) through the National
Disease Research Interchange (Philadelphia, PA, U.S.A.).
Full thickness articular cartilage slices were aseptically
collected and placed in DPBS with 2× antibiotics for
30 min. Cartilage disks (5–7 mg) were dissected from the
cartilage using a sterile leather punch (Libertyville Saddle
Shop, Libertyville, IL, U.S.A.). Disks were transferred to
96-well flat bottomed plates (Nunc, Denmark) containing
DMEM supplemented with antibiotics and 10% FBS. This
medium was changed 48–72 h later to DMEM with 0.5%
FBS and samples to be tested were added 24 h later.Proteoglycans (PGs), prostaglandin E2 (PGE2) and/or
nitric oxide (NO) levels in the cartilage explant super-
natants were determined 72 h after the addition of the
samples being evaluated. IL-1 stimulation of bovine and
human cartilage was performed using IL-1 and IL-1
respectively.19
Bovine and human chondrocytes were isolated from
cartilage as described elswhere for human chondro-
cytes.20,21 Briefly, cartilage was cut into small pieces and
chondrocytes were liberated by sequential treatment with
hyaluronidase (0.2% in DMEM without FBS) for 30 min;
pronase E (0.25% in DMEM without FBS) for 30 min;
collagenase D (0.2% in DMEM with 10% FCS) for 20 h at
37°C. No effort was made to separate different layers of
cartilage. Cells were washed twice in DMEM with 10%
FCS. Viability was determined by trypan blue exclusion.
For isolation of RNA, monolayer cultures of chondro-
cytes were used. Chondrocytes were seeded into six-well
tissue culture grade plates (Corning, Cambridge, MA,
U.S.A.) at a concentration of 2×106 cells/ml (4 ml/well) in
Ham’s F12 containing 10% fetal bovine serum, 50 g/ml
ascorbic acid and antibiotic/antimycotic. Cells were allowed
to adhere and cultured for 72 h at 37°C in 5% CO2. The
medium was then replenished and the chondrocytes were
treated with the indicated doses of SB 242235 for 30 min
followed by stimulation with IL-1. The cells were incubated
at 37°C in 5% CO2 atmosphere for 4 h. The cells were
homogenized in Triazol reagent (Molecular Research
Center, Cincinnati, OH, U.S.A.)−0.5 ml/well for the isolation
of RNA.[35S]-SULFATE INCORPORATION INTO GLYCOSAMINOGLYCANS
The synthesis of sulfated glycosaminoglycans (GAGs)
was measured in bovine cartilage by determining the
incorporation of [35S]-sulfate into cetylpyridiniumchloride-
precipitable (CPC) GAGs.22 The cartilage was labeled for
the last 18 h of culture with 0.5 uCi Na235SO4/well (New
England Nuclear, Boston MA, U.S.A.; sp.act. 1050 Ci/
mmol). Following removal of the medium, the explants
were washed twice in PBS and then 200 l papain (Sigma,
St Louis, MO, U.S.A.; 250 g/ml suspension) was added
and then incubated at 60°C for 6 h. The digest was then
transferred to 6 ml polypropylene tubes (Becton Dickinson,
Franklin Lakes, NJ, U.S.A.). To this digest, 1 ml of 1% CPC
(Sigma) was added and incubated at 37°C for 60 min. The
precipitate was washed twice with CPC (1%). The precipi-
tate was dissolved in NCS tissue solubilizer (Amersham,
Arlington Heights, IL, U.S.A.) and placed in a 45°C
water bath for 30 min. The amount of [35S]-sulfate was
determined by liquid scintillation counting.QUANTITATION OF GLYCOSAMINOGLYCANS
GAG levels in the culture media were determined by
the amount of polyanionic material reacting with DMMB.23
This measurement reflects both enhanced breakdown as
well as enhanced synthesis. Explant supernatants were
removed and 50 l of a 1–40 dilution (made in 50 mM
sodium acetate buffer) was combined with 200 l of DMMB
solution. Samples were examined spectrophotometrically
at 535 nm (SpectraMax, Molecular Devices, Sunnyvale,
CA, U.S.A.). Results are reported as g GAG/mg cartilage.
NITRITE DETERMINATION
NO production was measured by estimating the stable
NO metabolite, nitrite, in conditioned medium using aBecause of the improved kinase selectivity of SB 242235
over SB 203580 for p38 MAP kinase inhibition, we have
now used this compound to extend our previously reported
studies on the inhibition of NO production and iNOS gene
expression in bovine cartilage/chondrocytes.11 We have
profiled SB 242235 for its effect on proteoglycan (PG)
synthesis as well as IL-1-induced PG breakdown in the
bovine system; we also examined its effects on human
cartilage NO production and iNOS expression. In these
studies we have also used hymenialdisine, a natural prod-
uct that inhibits NO and iNOS in bovine chondrocytes,18 as
a positive control and to help further characterize the
mechanism of action of SB 242235. We now report that
selective inhibition of p38 MAP kinase has differential
effects on NO production and iNOS gene expression in
bovine and human chondrocytes.
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tion.24 Following culture of the cartilage explants/
chondrocytes for the times indicated, 50 l of the culture
supernatants or sodium nitrite standard dilutions were
mixed with 50 l Griess reagent (1% sulfanilamide, 0.1%
naphthyl ethylenediamine dihydrochloride, and 5% H3PO4)
and incubated for 10 min at room temperature. Nitrite
concentrations were determined by measuring absorbance
at 540 nm in an ELISA reader (Molecular Devices,
Sunnyvale, CA, U.S.A.). The detection limit of the test was
2 M NO−2 . Values are expressed as M nitrite released
per mg cartilage for explant cultures and M/well for
monolayer cultures.
PROSTAGLANDIN E2 MEASUREMENT
For measurement of PGE2 levels, bovine and human
chondrocytes were established at 1×104 cells per well in
200 l of Ham’s F12 in 96-well plates. Following a 24 h
incubation the medium was replenished and IL-1 and
compounds were added for an additional 24 h. The produc-
tion of PGE2 in the cell free supernatant was then analysed
using an ELISA kit from Cayman Chemical Chemical Co.,
Ann Arbor, MI, U.S.A.IMMUNE COMPLEX KINASE ASSAYS
Human chondrocytes (1×107 cells) were established in
10 cm tissue culture petri dishes in DMEM with 10% FBS
and stimulated with 20 ng/ml of IL-1 for varying periods of
time. Immune complex kinase assays were performed
essentially as described previously.11 Briefly, the cells
were washed twice in PBS and then solubilized on ice
in lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl,
1% Triton X-100, 10% glycerol, 2 mM EDTA, 25 mM
-glycerophosphate, 20 mM NaF, 1 mM sodium ortho-
vanadate, 2 mM sodium pyrophosphate, 1 mM phenyl-
methylsulfonyl fluoride, 10 g/ml leupeptin, 5 U/ml
aprotinin) and centrifuged at 15 000×g for 20 min at 4°C.
Endogenous kinases were precipitated from cell lysates
using anti-p381 or anti-MAPKAP kinase-2 antibodies
(kindly supplied by Dr Jacques Landry, Quebec, Canada)
bound to protein-A agarose for 4 h at 4°C. The beads were
washed twice with lysis buffer and twice with kinase buffer
(25 mM Hepes pH 7.4, 25 mM MgCl2, 25 mM -glycero-
phosphate, 100 mM sodium orthovanadate, 2 mM DTT).
The immune-complex kinase assays were initiated by the
addition of 25 l of kinase buffer containing 2 g of GST-
ATF2 for p38 or 2 g of the small heat shock protein 27
(HSP27, StressGen Biotechnology, Ontario, Canada) for
MAPKAP kinase-2 as substrate and 50 M [-32P] ATP
(20 Ci/mmol, Amersham). After 30 min at 30°C, the reac-
tion was stopped by the addition of SDS sample buffer and
the phosphorylated products were resolved by SDS-PAGE
and visualized by Phosphorimaging (Molecular Dynamics).
For inhibition in intact cells, the cells were pre-treated
with different concentrations of SB 242235 for 30 min prior
to stimulation with IL-1. Recombinant GST-ATF2 was
expressed in E. coli and purified over Glutathione
sepharose 4B (Pharmacia) chromatography according to
manufacturer’s instructions.ISOLATION OF CHONDROCYTE RNA AND NORTHERN BLOT
ANALYSIS
Total RNA was isolated from chondrocytes treated with
IL-1 and SB 242235 and the RNA concentration and puritywere determined spectrophotometrically. All RNA samples
had an A260/A280 ratio >1.8. Approximately 10 g of the
RNA samples were electrophoresed in 1% agarose
gels containing 2.5% formaldehyde, 20 mM 3-(N-
morpholino)propanesulfonic acid, 5 mM sodium acetate
and 1 mM EDTA pH 7.0. After electrophoresis, the RNA
was transferred to positively charged nylon membranes
(Bio-Rad, Hercules, CA, U.S.A.). Membranes were pre-
hybridized for 1–2 h at 68°C with ExpressHyb (Clonetech,
Palo Alto, CA, U.S.A.). Hybridization was performed under
identical conditions to pre-hybridization with addition of
32P-labeled (Amersham) probe specific to bovine iNOS.
The 372 bp probe was graciously provided by Dr T. Jungi
(University of Berne, Berne, Switzerland)25 and corre-
sponds to nucleotides 682-1053 of the human iNOS
cDNA.26 Radiolabel on the blots was analysed and
integrated using phosphorimaging.STATISTICAL ANALYSIS
Comparisons between treated and control groups were
determined by Student’s t-test, with P values less than 0.05
considered significant. All experiments were performed at
least three times and the results shown are those from
representative experiments.ResultsPROTEOGLYCAN SYNTHESIS AND BREAKDOWN IN BOVINE
CARTILAGECartilage explants were established in 96-well flat-
bottomed plates in DMEM with 10% FBS for 48 h and then
transferred to medium containing 0.5% FBS. Following a
24 h incubation period, the explants were treated with
100 ng/ml IL-1, SB 242235 alone which was added at 2.5,
5, 10 and 20 M or a combination of SB 242235 and IL-1.
The explants were incubated for an additional 72 h and
then pulsed with [35S]-sulfate for 18 h. As shown in Table I,
there was an 85% inhibition of PG synthesis with IL-1
treatment, whereas treatment with SB 242235 did not result
in significant inhibition at any dose. In addition, when SB
242235 was added to the cultures in combination with
IL-1, there was no modification of the IL-1 inhibitory
effect. To determine the effect of SB 242235 on IL-1
stimulated PG breakdown, the explants were established in
a similar manner and treated with IL-1 with and without SB
242235 at doses ranging from 0.06 to 20 M. The explantsTable I
IL-1, but not SB 242235, inhibits PG synthesis in bovine cartilage
explant cultures
Treatment 35S-incorporation
into GAGs (mean±S.D)
% Inhibition
Control 33,395±6905
IL-1 100 ng/ml 5186±2350 85% P<0.001
SB 242235 20 M 33,026±4377
10 M 30,543±6431
5 M 32,291±6845
2.5 M 30,583±6933
SB 242235 20 M+IL-1 5641±1887 83% P<0.001
10 M+IL-1 5873±1778 82% P<0.001
5 M+IL-1 5649±1869 83% P<0.001
2.5 M+IL-1 5982±1653 82% P<0.001
Osteoarthritis and Cartilage Vol. 8 No. 6 437Fig. 1. (a) Treatment with SB 242235 does not inhibit IL-1 induced
PG breakdown from bovine cartilage explants. BB94 was added as
a positive control. Compounds were added at the start of a 72 h
culture. Data are means and S.D. of six replicates per group. (b)
Dose-dependent inhibition of IL-1-induced NO release from
bovine cartilage explants by SB 242235. Compound treatment was
initiated at the start of a 72-h culture. Data are means and S.D. of six
replicates per treatment. *P<0.05; **P<0.01; ***P<0.001.Fig. 2. Time course of inhibitory effect of SB 242235 on IL-1-
stimulated NO release from bovine cartilage explants. SB 242235
was added either with IL-1 (0 time) or at different time intervals
after IL-1. NO release was measured 72 h after the addition of
IL-1. Data are means and S.D. of six replicates per treatment.
**P<0.01; ***P<0.001.Fig. 3. Effect of compounds with differing mechanisms of action on
IL-1-stimulated NO release from bovine cartilage explants. Com-
pounds were added at the initiation of a 72-h culture. Data are
means and S.D. of six replicates per treatment. *P<0.05; **P<0.01;
***P<0.001.were incubated for 72 h and GAG release into the super-
natants was determined. In the presence of IL-1, GAG
release was increased by 15-fold compared with that in the
untreated control cultures. SB 242235 had no effect at any
of the doses examined [Fig. 1(a)] whereas the MMP
inhibitor, BB94, was able to decrease this release by 80%.
NO PRODUCTION BY BOVINE ARTICULAR CARTILAGE AND
CHONDROCYTES
Cartilage explants were established in culture and stimu-
lated with IL-1 (100 ng/ml) as described for the PG break-
down experiments. In the presence of IL-1, NO production
in the supernatants, measured by nitrite release, was
approximately eight-fold higher than in unstimulated control
cultures. This stimulation of NO production was inhibited by
the incorporation of NMMA, a competitive inhibitor of all
isoforms of NOS, in the cultures. SB 242235 was also able
to inhibit IL-1 stimulated NO production with an IC50 of
approximately 1 M with maximal inhibition being observed
at 20 M [Fig. 1(b)]. For SB 242235 to significantly inhibit
NO production in the BAC cultures, the compound had to
be present early in the incubation period (up to 9 h after theaddition of IL-1) and the inhibitory effect was lost when the
compound was added 24 h after IL-1 stimulation (Fig. 2).
To investigate the mechanism of action of the inhibition
of NO release, several different classes of inhibitors were
utilized for comparison with the p38 MAP kinase inhibitor
SB 242235 (Fig. 3). Inhibition with SB 242235 was approxi-
mately 70% at 10 M. The iNOS inhibitor NMMA inhibited
NO production by 100% and herbimycin, a protein tyrosine
kinase inhibitor, reduced NO by approximately 50% at
5 M which is the highest non-toxic concentration in vitro.
Hymenialdisine, which inhibits PKC27 and PTK (S. Kassis,
unpublished observations), and which was shown pre-
viously to inhibit NO production in bovine explants,18 was
also included as a positive control and inhibited by about
75%. No statistically significant inhibition was observed
with the MEK-1 inhibitor, PD 98059, the PKC inhibitor,
calphostin or the PKA inhibitor, KT 5720.
*P<0.05; ***P<0.001.
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isolated chondrocytes as in the cartilage explants, bovine
chondrocytes were isolated from the cartilage by enzymatic
digestion and established in monolayer in 48-well culture
plates. Following a 48 h incubation period, IL-1 and com-
pounds were added and NO production evaluated 72 h
later. There was a 15-fold increase in NO production by
IL-1-stimulated chondrocyte cultures, which was inhibited
by SB 242235 with an IC50 of approximately 0.6 M.
NMMA (1 mM) completely inhibited IL-1 stimulated NO
production (Fig. 4).EXPRESSION OF BOVINE INOS MRNA
To determine if the regulation of iNOS by SB 242235
occurred at the level of transcription we examined the
expression of iNOS mRNA in response to IL-1 by Northern
blot analysis. Figure 5 shows that there was a significant
increase in expression of iNOS mRNA following treatment
with IL-1 and that this induction was inhibited in a
dose-related manner by SB 242235 with an IC50 of
approximately 0.1 M.ACTIVATION OF P38 MAP KINASE ACTIVITY BY IL-1 AND INHIBITION
BY SB 242235 IN HUMAN CHONDROCYTES
Previously, we demonstrated that IL-1 activates p38
MAP kinase in bovine chondrocytes and that this is inhib-
ited by the CSAID, SB 203580.11 Therefore, to evaluate the
effects of SB 242235 on IL-1-induced NO production in
human cartilage we first examined the effects of IL-1 on
p38 MAP kinase in human chondrocyte monolayer cul-
tures. IL-1 induced a rapid activation of p38 MAP kinase
with a 19-fold activation achieved within 5-min treatment. At
60 min post-activation, p38 activity declined, but was still
seven-fold higher than the basal level [Fig. 6(a), upper
panel]. Similarly, MAPKAP K2, which is activated by, and is
a physiological substrate of, p38,5 was also significantly
activated (seven-fold) within 5 min of IL-1 treatment.MAPKAP K2 activity was ∼five-fold over the basal level at
60 min [Fig. 6a, lower panel]. To show that SB 242235
inhibited intracellular p38 activity, human chondrocytes
were treated with different doses of SB 242235 prior to
stimulation with IL-1 for 15 min. MAPKAP K2 was
then isolated from these cells and assayed using HSP27 as
a substrate. SB 242235 dose-dependently inhibited the
activation of MAPKAP K2 with an IC50 of 1.0 M [Fig. 6(b)].NO PRODUCTION BY HUMAN CARTILAGE AND CHONDROCYTES
Since we had observed inhibition of both p38 MAP
kinase activity and inhibition of NO production in the bovine
system, it was of interest to determine the effects of SB
242235 on IL-1 stimulated NO production and iNOS gene
expression in human tissues. Human cartilage explants
and cartilage-derived chondrocytes were established in
culture in a manner identical to the bovine cultures. IL-1
and compounds were added as for the bovine cartilage and
NO release measured 72 h later. IL-1 treatment increased
NO production 7–8-fold above the control unstimulated
explants. This was inhibited by NMMA (1 mM) and by
hymenialdisine with about 50% inhibition at 5 M. There
was some inhibition of NO production by SB 242235 but
only at the 20 M dose and there was no inhibition at lower
doses [Fig. 7(a)]. Furthermore, SB 242235 also failed to
inhibit NO production in primary human chondrocyte cul-
tures, whereas inhibition was observed with NMMA and
hymenialdisine [Fig. 7(b)].Fig. 4. Dose-dependent inhibition of IL-1-induced NO production
from bovine articular chondrocytes. Chondrocytes were estab-
lished in monolayer cultures and treated at the initiation of a 72 h
culture. Data are means and S.D. of four replicates per treatment.Fig. 5. Expression of IL-1-stimulated iNOS message in bovine
chondrocytes is inhibited in a dose-related manner by SB 242235.
Chondrocytes were established in monolayer culture (8×106 cells
in 4 ml) in six-well plates for 72 h. Cells were then stimulated with
IL-1 (100 ng/ml) and treated with SB 242235 for 4 h and RNA
isolated. The Northern blot shows that the radiolabeled iNOS
probe is associated with the 4.2-Kb message and dose-related
inhibition by SB 242235. Upper panel; control untreated (lane 1);
IL-1 control, 100 ng/ml (lane 2); IL-1 plus SB 242235 at 0.001,
0.01, 0.1, 1 and 10 M (lanes 3–7). Lower panel; the 28S ribo-
somal RNA band for each lane is shown below.EXPRESSION OF HUMAN INOS MRNA
Although SB 242235 did not inhibit IL-1-induced NO
production in the human chondrocyte cultures, we still
thought it was important to examine iNOS message in the
cultures and compare it to the positive control, hymenialdi-
sine. As shown in Fig. 8(a) and (b), no iNOS gene expres-
sion was observed in the untreated control chondrocytes
but a dramatic induction of gene expression was observed
with 10 ng/ml of IL-1. Unlike the inhibitory effects
Osteoarthritis and Cartilage Vol. 8 No. 6 439observed with bovine chondrocytes, there was no signifi-
cant inhibition of iNOS gene expression observed following
treatment with SB 242235 at 2.5, 5, 10 and 20 M [Fig.
8(a)]. In contrast, treatment with hymenialdisine inhibited
iNOS gene expression in a dose-related manner
[Fig. 8(b)].INHIBITION OF PGE2
To examine the effect of p38 kinase inhibition on the
production of another proinflammatory mediator, PGE2,
bovine and human chondrocytes were established in
monolayer culture and treated with IL-1 and SB 242235.
Inhibition of IL-1 induced PGE2 was observed in both
cultures. In the bovine chondrocytes the IC50 for inhibition
was ∼0.1 M and almost complete inhibition was observed
at 10 M [Fig. 9(a)]. In the experiments using human
chondrocytes, however, the IC50 was 1–3 M, which was
higher than that observed with the bovine cells. In addition,
only about 50% inhibition of the PGE2 production could be
suppressed by SB 242235 at 1 M and higher concen-
trations of 3 and 10 M did not result in an increase in
suppression [Fig. 9(b)].Fig. 6. Activation of p38 MAPK by IL-1 in human chondrocytes.
Chondrocytes (1×107 in 10 ml of medium) were plated in 100 mm
plates and allowed to adhere for 24 h. Cells were treated with
20 ng/ml of IL-1 for different time periods as indicated. At the end
of the incubation, cells were harvested, p38 or MAPKAP kinase-2
was immunoprecipitated, and the immune complex kinase assay
was performed with GST-ATF2 and HSP27 as substrates as
described in Materials and methods. The upper panel (a) shows
the time course of activation of p38 (GST-ATF2 phosphorylation)
and MAPKAP kinase-2 (HSP27 phosphorylation). Lane 1, control
untreated; lanes 2–5, IL-1 treated at 5, 15, 30 and 60 min. (b)
Chondrocytes were pre-treated with the indicated concentrations
of SB 242235 and then exposed to IL-1 for 15 min. Cells were
harvested and MAPKAP kinase-2 immunoprecipitated with HSP27
as a substrate as described in Materials and methods. The IC50 of
inhibition of the activation of MAPKAP K2 which reflects the
inhibition of p38 activity in the cells was calculated to be ∼1 M.Fig. 7. SB 242235 does not inhibit IL-1 induced NO production in
(a) human articular cartilage explants or (b) human articular
chondrocytes. Compounds were added at the initiation of a 72 h
culture. Control compounds were NMMA and HYM. Data are mean
and S.D. of six replicates per treatment. *P<0.05; ***P<0.001.Discussion
The pyridinyl imidazoles inhibit the p38 kinase-mediated
synthesis of cytokines such as IL-1 and TNF- from human
monocytes with IC50s of 0.1–1 M.1,2 These compounds,
termed CSAIDs, inhibit TNF synthesis at the translational
rather than the transcriptional level28,29 and their target is
known as CSBP/p38 kinase.1 One of the physiologic sub-
strates of CSBP/p38 is MAPKAP kinase-2, which in turn,
phosphorylates hsp27. In stress-stimulated cells, SB
203580, a widely used pyridinyl imidazole CSAID, inhibits
the phosphorylation and activation of MAPKAP kinase-2 by
p38 and subsequently the phosphorylation of hsp27.
IL-1 and TNF play predominant roles during inflam-
matory responses and autoimmune disease.30 The role
of cytokines in rheumatoid arthritis (RA) is well docu-
mented and they may also have a role in osteoarthritis
(OA).31–33 These cytokines can induce PG degradation,
inhibit PG synthesis and induce matrix metalloproteinases
(MMPs)34–39 resulting in degradation of both cartilage and
bone matrix. One of the mechanisms by which cytokines
elicit their proinflammatory effects is by stimulation of the
production of nitric oxide. The inducible form of nitric oxide
synthase (iNOS) synthesizes high levels of NO in response
to IL-1 and TNF. IL-1 has been shown to induce the
release of NO from various tissues including bone, carti-
lage and cartilage-derived chondrocytes in a number of
440 A. M. Badger et al.: Role of p38 in nitric oxide productionFig. 8. (a) Expression of IL-1-stimulated iNOS message in human
chondrocytes is not inhibited by SB 242235. Chondrocytes were
established in monolayer culture and treated as described in the
legend to Fig. 5(a). Upper panel; control untreated (lane 1); IL-1
control, 20 ng/ml (lane 2); IL-1 plus SB 242235 at 2.5, 5, 10 and
20 M (lanes 3–6). Lower panel; the 28S ribosomal RNA band for
each lane is shown below. (b) Expression of IL-1-stimulated iNOS
mRNA in human chondrocytes is inhibited by hymenialdisine.
Upper panel; control untreated (lane 1); IL-1 control, 20 ng/ml
(lane 2); IL-1 plus hymenialdisine at 0.6, 1.25, 2.5 and 5 M
(lanes 3–6). Lower panel; the 28S ribosomal RNA band for each
lane is shown below.Fig. 9. Inhibition of IL-1 induction of PGE2 in (a) bovine and (b)
human chondrocytes. Chondrocytes were established in mono-
layer cultures in 96-well plates and stimulated with IL-1 for bovine
and IL-1 for human chondrocytes. The cultures were incubated
for 24 h, the medium replenished and then treated for 24 h with
IL-1 and SB 242235. Data are mean and S.D. of six replicates per
group. *P<0.05; **P<0.01; ***P<0.001.species,40–43 which can then contribute to tissue regulation
and damage. NO may activate MMPs responsible for
proteoglycan degradation in articular cartilage44 and may
mediate the IL-1-induced inhibition of PG synthesis in rabbit
articular cartilage in vitro.45 However, our own studies, as
well as those described previously by others using bovine
and rabbit articular cartilage,46,47 suggest that inhibition of
NO production with NMMA does not inhibit IL-1-induced PG
breakdown. The role of NO in vivo in inflammatory disease
has also been well documented. For example, inhibitors of
iNOS have been shown to protect against inflammation and
cartilage matrix loss in inflammatory arthritides.48–51
In a previous study, we reported the inhibition of IL-1
induced NO production and of iNOS gene expression by
the CSAID, SB 203580 in bovine cartilage.11 This com-
pound also inhibited IL-1 induction of p38 MAP kinase
activity in bovine chondrocytes with a similar IC50, confirm-
ing inhibition of p38 as a potential mechanism for the
observed inhibition of iNOS. We have now extended these
observations by using a more selective inhibitor of p38
kinase, SB 242235, which has no effects on ERK and JNK
and has differential inhibitory effects on the four known
homologs of CSBP/p38 MAP kinase, with p38 MAP
kinase being 10-fold less sensitive than p38 while p38
and  MAP kinases are insensitive (Lee et al., unpublishedobservations). SB 242235 was evaluated for its effects, not
only on NO production and iNOS gene expression, but also
on PG synthesis and IL-1-induced PG breakdown in
bovine cartilage. We also extended our previous obser-
vations in bovine cartilage, by comparing the effect of SB
242235 on NO production and iNOS in human cartilage. It
should be noted that in these experiments, IL-1 was used
for the studies with bovine tissue and IL-1 was used for
the human cultures, as these have been accepted as the
most appropriate isoforms of IL-1 to be used for the two
species.19 The concentrations of IL-1 used also differed for
the two species in that 100 ng/ml was used for the bovine
experiments, because very high concentrations have been
shown to be required for maximum effects in this species52
and this has been confirmed by us (unpublished obser-
vations). For human studies however, lower concentrations
of 10–20 ng/ml provided maximal effects.
We found that SB 242235 at doses up to 20 M had no
statistically significant effect on PG synthesis in bovine
cartilage explants as measured by [35S]-sulfate incorpor-
ation into GAGs. This is in contrast to studies by Ridley
et al.53 who described inhibition of PG synthesis in bovine
nasal cartilage by SB 203580. This difference is probably
due to the less selective CSAID used in the studies, as we
often observed a slight decrease in isotope incorporation
Osteoarthritis and Cartilage Vol. 8 No. 6 441using SB 242235 at the high concentrations of 10 and
20 M, but this was not statistically significant. Alternatively,
it may have been due to the difference in the type of
cartilage used (nasal vs articular). When SB 242235 was
added to the cultures in combination with IL-1, there was
no increase in the inhibitory effect of the cytokine on PG
synthesis and no ameliorative effects were observed on the
inhibition.
In experiments to determine the effect of SB 242235 on
IL-1-induced PG breakdown in bovine explants we found
that no changes occurred at doses up to 20 M. This
supports data reported previously by Ridley et al.53
describing the lack of effect of SB 203580 on IL-1 stimu-
lated PG breakdown in bovine nasal cartilage explants.
However, while no effect was observed on IL-1 mediated
release of PG, there was a dose dependent inhibiton of
IL-1 stimulated NO production and iNOS gene expression
in both cartilage explants and chondrocyte cultures with
IC50s of 0.6–1 M. The data suggest that IL-1 mediated
iNOS expression is under the control of p38 in bovine
chondrocytes; whereas the IL-1 driven matrix degradation
and inhibition of synthesis is not controlled by this kinase. It
has previously been reported that IL-1 mediated proteogly-
can degradation is mediated by an ADAMTS aggreca-
nase.54 The data with SB 242235 suggest that IL-1-
stimulated increase in aggrecanase activity does not
require activation of p38 kinase.
Surprisingly, in studies with human cartilage and
cartilage-derived chondrocytes, we were unable to demon-
strate an inhibition of IL1--induced NO production by SB
242235 except at the highest dose of 20 M or with SB
203580 (A. Badger, unpublished observation). This was
despite the fact that there was a clear inhibition of IL-1
induced p38 MAP kinase by SB 242235. In keeping with
this finding we were unable to demonstrate an inhibition of
IL-1-induced iNOS gene expression in human chondro-
cytes at doses of up to 20 M. On the other hand, a clear
inhibition of IL-1-stimulated NO production and iNOS
gene expression was observed with hymenialdisine. There-
fore, unlike bovine chondrocytes, the induction of iNOS by
IL-1 in human chondrocytes appears not to involve p38
MAPK pathways. In addition, iNOS regulation in human
chondrocytes and perhaps in bovine chondrocytes includes
PTK, as hymenialdisine has been shown to inhibit PKC27
and PTK (S. Kassis, unpublished observation) but not p38
MAP kinase (S. Kumar, unpublished observation). The
inhibitory activity of hymenialdisine for NO and iNOS in
bovine cartilage was clearly shown not to be due to
inhibition of PKC but may, in part, be due to inhibition of
PTK.18 Thus, there appear to be species-specific, distinct
pathways of iNOS induction and regulation in bovine and
human chondrocytes, with bovine cells using p38 and PTK
and human cells utilizing only PTK. Recently, hymenialdi-
sine was shown to inhibit IL-8 production in the human
macrophage cell line, U937, by inhibition of nuclear
factor-B (NF-b).55 Hymenialdisine was also shown to
inhibit NF-B-mediated, IL-1 -stimulated PGE2 in human
rheumatoid synovial fibroblasts.56 Therefore, the effects
observed on chondrocyte iNOS may also be due to regu-
lation of NF-B, as has been observed previously in several
cell lines transfected with a 3.2 kb putative promoter of the
human iNOS gene.57
It is important to note that the observed inability of the
CSAIDs to affect NO production in human cartilage was not
a general phenomenon for these compounds with regard
to inhibition of proinflammatory mediators in human cells.
This was seen by the finding that IL-1-stimulated PGE was2inhibited by SB 242235 in both bovine and human chondro-
cyte cultures. Therefore, SB 242235 is able to reach p38
kinase in these cells and cause a biological effect.
Of particular interest to these studies is a report describ-
ing the down-regulation of the spontaneous release of NO
from human OA cartilage by SB 203580.58 The spon-
taneous release of NO was apparently due to up-regulated
IL-1 in the OA cartilage. However, the authors did not
examine the effects of SB 203580 on extrinsically added
IL-1 induced NO release or iNOS gene expression.
Differences between species, and also differences
between cell types and stimuli, with regard to CSAID
inhibition of iNOS, have been reported by others. For
example an early CSAID compound, SK&F 86002, had no
effect on the induction of iNOS expression in mouse
macrophages stimulated with IFN- and TNF.59 In rat
endotoxin-stimulated primary glial cell cultures both
PD 98059 and SB 203580 were able to partially suppress
NO and iNOS and the combination of the MEK-1 and p38
inhibitors almost completely blocked glial production of NO
and iNOS gene expression.60
In conclusion, it has been well documented that the
CSAIDs, by inhibiting p38 MAP kinase, control the produc-
tion of, and the effects of, cytokines such as IL-1 and TNF
and by this mechanism they may well have therapeutic
effects in a number of inflammatory and chronic diseases.
However, as seen in previously reported studies and in the
experiments reported here, there are instances where
CSAID inhibition of certain metabolic pathways is not
consistent across cells, stimuli or species. The finding that
IL-1-induced NO production and iNOS gene expression in
human chondrocytes are refractory to the effects of
CSAIDs indicates that one must be cautious about extrapo-
lating across species. Furthermore, IL-1 induced iNOS
production and matrix degradation and/or synthesis may be
controlled through two independent pathways within
chondrocytes.Acknowledgments
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